Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?

Author: Kirkali Ziya   Tüüzel Emre  

Publisher: Future Medicine

ISSN: 1479-6694

Source: Future Oncology, Vol.5, Iss.6, 2009-08, pp. : 871-888

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract